What is 10x Genomics, Inc.'s D&A?

10x Genomics, Inc. (TXG) reported D&A of $9.96M in Q1 2026.

How has 10x Genomics, Inc.'s D&A changed year-over-year?

10x Genomics, Inc.'s D&A increased by 24.1% year-over-year, from $8.02M to $9.96M.

What is the long-term trend for 10x Genomics, Inc.'s D&A?

Over 4 years (2021 to 2025), 10x Genomics, Inc.'s D&A has grown at a 14.4% compound annual growth rate (CAGR), from $21.12M to $36.2M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

10x Genomics, Inc. TXG D&A

D&A at other companies

TEC

Bio-TechneTECH

$24.17M-12.3%

BrukerBRKR

$58.3M+15.7%

IlluminaILMN

$51M-1.9%

Twist Bioscience CorporationTWST

$6.41M+0.2%

RevvityRVTY

$105.06M+7.8%

Agilent TechnologiesA

$67M-8.2%

Other financials

Income statement

See full

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Balance sheet

See full

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Cash flow

See full

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Valuation

See full

Market cap$4.41B+154%

Profitability

See full

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Returns & leverage

See full

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 10x Genomics, Inc.'s D&A?: 10x Genomics, Inc. (TXG) reported D&A of $9.96M in Q1 2026.
How has 10x Genomics, Inc.'s D&A changed year-over-year?: 10x Genomics, Inc.'s D&A increased by 24.1% year-over-year, from $8.02M to $9.96M.
What is the long-term trend for 10x Genomics, Inc.'s D&A?: Over 4 years (2021 to 2025), 10x Genomics, Inc.'s D&A has grown at a 14.4% compound annual growth rate (CAGR), from $21.12M to $36.2M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.